ALSENLITE: Senolytics for Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-06

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being done to evaluate the safety and feasibility of using Dasatinib and Quercetin together in subjects with Mild Cognitive Impairment (MCI) or Alzheimer's disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease

NCT05422885

Aging

COMPLETED PHASE1/PHASE2

Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease

NCT03090516

Alzheimer's

UNKNOWN PHASE2/PHASE3

Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease

NCT02162251

Alzheimer's Desease

COMPLETED

Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

NCT00051909

Alzheimer's Disease

COMPLETED PHASE2

Safety of Donepezil in Patients With Dementia Associated With Cerebrovascular Disease

NCT00188812

Dementia Associated With Cerebrovascular Disease

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The underlying processes driving chronic neurodegeneration in Alzheimer's disease (AD) and related neurodegenerative disorders are largely unknown. Aging is the major risk factor for AD. Moreover, individuals with AD suffer from significantly more co-morbid conditions than demographically matched older adults. This study is an open-label pilot study of intermittent administration of the senolytic drug regimen Dasatinib (D) + Quercetin (Q) in symptomatic adults over 55 with clinical diagnosis of probable Alzheimer's Disease and Alzheimer's biomarker positivity by tau-PET.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Cognitive Impairment Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dasatinib plus Quercetin Treatment Goup

Subjects with MCI or Alzheimer's disease will take Dasatinib and Quercetin by mouth at the same times for 2 days out of every 15 days for 6 cycles lasting for a total of 77 days (12 concurrent doses of each agent).

Group Type EXPERIMENTAL

Dasatinib

Intervention Type DRUG

100 mg capsule daily for 2 consecutive days administered orally every 15 days (2 days on drug, 13 days off) for 6 cycles

Quercetin

Intervention Type DRUG

Four 250 capsules once daily (total daily dosage 1000 mg) administered orally for 2 consecutive days every 15 days (2 days on drug, 13 days off) for 6 cycles

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dasatinib

100 mg capsule daily for 2 consecutive days administered orally every 15 days (2 days on drug, 13 days off) for 6 cycles

Intervention Type DRUG

Quercetin

Four 250 capsules once daily (total daily dosage 1000 mg) administered orally for 2 consecutive days every 15 days (2 days on drug, 13 days off) for 6 cycles

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and women of age 55 years and older at the time of enrollment
2. Clinical diagnosis of symptomatic probable AD (MMSE 26 to 15 or Short Test of Mental Status 31 to 15 inclusive and/or Clinical Dementia Rating Scale/CDR = 0.5 to 2, inclusive)
3. Not on cholinesterase inhibitors or memantine; or if on cholinesterase inhibitors and/or memantine, on a stable dose for at least three months
4. Body Mass Index (BMI) within range of 19 - 50 kg/ m2
5. Participants must be accompanied by a LAR designated to sign informed consent and to provide study partner reported outcomes at all visits
6. Participants must have no plans to travel over the \~3 months between Visits 3 and 14 that interfere with study visits
7. Tau positivity by brain PET imaging
8. Adequate blood counts i.e. platelets \> 50,000 per microliter; HB \> 9/dL, and ANC \> 1000 per microliter
9. Availability and consent from a LAR.

Exclusion Criteria

1. Unwilling or unable to give informed consent
2. Pregnancy
3. QTc \> 450 msec on baseline ECG
4. MRI contraindications
5. Presence of uncontrolled psychiatric disorder (as per clinical judgment)
6. Presence of uncontrolled systemic lupus erythematosus (as per clinical judgment)
7. Substance or alcohol abuse (current alcohol use \> 3 alcoholic beverage/day or \> 21 per week and as per clinical judgment)
8. Hearing, vision, or motor deficits despite corrective devices (as per clinical judgment)
9. Myocardial infarction, angina, stroke, or transient ischemic attack in the past 6 months
10. Chronic heart failure (as per clinical judgment)
11. Neurologic, musculoskeletal, or other condition that limits subject's ability to complete study physical assessments (as per clinical judgment)
12. Positive SARS-CoV-2 test within 30 days prior to enrollment
13. AST/ALT \> 2.5x upper limit normal
14. Presence of significant liver disease with total bilirubin \> 2X upper limit or as per clinical judgment
15. Inability to tolerate oral medication (as per clinical judgment)
16. Abnormality in any of the screening laboratory studies (see section 6.21.2) or as per clinical judgment
17. Malabsorption (as per clinical judgment)
18. Known human immunodeficiency virus infection (as per clinical judgment)
19. Known active hepatitis B or C infection
20. Invasive fungal or viral infection (as per clinical judgment)
21. Known hypersensitivity or allergy to D or Q
22. Uncontrolled pleural/pericardial effusions or ascites (as per clinical judgment)
23. New/active invasive cancer except non-melanoma skin cancers
24. Inability to tolerate oral medications (as per clinical judgment)
25. Currently taking AND unable to safely hold any of the medications listed in Appendix 1 during the days IP is administered and for 36 hours after IP administration.
26. Uncontrolled diabetes (defined as HbA1c \> 7% or as per clinical judgment).
27. Gastric bypass/reduction
28. Crohn's disease
29. Myopathies (increased or low calcium, vitamin D deficiency, elevated creatine kinase or ESR) (as per clinical judgment)
30. eGFR \< 10 ml/ min/ 1.73 m2
31. Creatinine clearance \< 60 mL/min/1.73 m2
32. Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.)
33. On antiplatelet agents (e.g., full dose Aspirin, Clopidogrel etc.). Baby aspirin (81 mg), if absolutely necessary from cardiac perspective, will be allowed
34. Presence of any condition that the Investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial

Involvement of special vulnerable populations: We will not involve special vulnerable populations, such as fetuses, neonates, pregnant women, children, prisoners, institutionalized individuals, or others who may be considered vulnerable populations except for patients with dementia. Therefore, availability and consent from a LAR is an inclusion criterion.

Minimum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No